Immunity certificates can become the new normal | “疫苗护照”要来了? - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT英语电台

Immunity certificates can become the new normal
“疫苗护照”要来了?

UK vaccine passport plans are sound but need skilful management
英国疫苗护照计划是好的,但管理能跟上吗?
00:00

Can countries that have vaccinated most of their adult population throw out the lockdown rule book and return to a pre-Covid 19 normal? That, at heart, is the question the UK — most advanced of the world’s big economies in immunisations — is grappling with as it considers plans for vaccine passports, or “Covid status certificates”. A vocal opposition warns these would be divisive and discriminatory. Given the risk of vaccine-resistant strains, however, some ongoing safeguards will be needed. Handled properly, a certification scheme incorporating both jabs and testing strikes a sensible balance.

Some form of vaccine passport already seems inevitable for international travel; several schemes are under way. The question is whether to require something similar for domestic venues. Under plans Boris Johnson’s government is considering for England, a digital or paper certificate would show if a person had been vaccinated, had a negative lateral flow or PCR test from that day or the day before, or was immune after contracting Covid in the previous six months.

This would be required to enter higher-risk environments such as theatres, sports stadiums, night clubs and music festivals, but not for public transport, public services or essential shops. It would not be needed, initially, for pubs — but might be introduced later as an option that could allow bars to operate at higher capacity. Scotland’s first minister Nicola Sturgeon says similar plans will be considered.

Several dozen dissenting MPs at Westminster say once the vulnerable are vaccine-protected, normal life should resume. By then, they suggest, the population can live with Covid as with annual flu outbreaks. Passports or certificates would unfairly divide society into the jabbed, who can swan into nightclubs and planes, and the unjabbed who must faff repeatedly with swabs.

Arguing coronavirus must one day be treated like the flu is right in the long run. But we are not there yet. Since vaccines emerged, so have new variants that are more contagious and sometimes more resistant to jabs. Even when immunisation programmes are done, large chunks of the population will not be vaccinated, including schoolchildren and those who cannot or choose not to receive the jab. Being vaccinated may not entirely prevent transmission. Vaccinating all countries will be the work of years, not months. While pools of infection exist, so does the risk of resistant outbreaks that could again swamp health systems.

That does not mean locking down everyone for ever more. It does mean aiming for a “new normal” that balances the rewards of vaccines in allowing economies to reopen with necessary controls on continued infections.

The government’s approach might cause brief delays for all entrants to some locations, and slightly greater inconvenience for some. But it would not cause serious discrimination since no one with immunity or negative Covid status would be barred. Inconvenience will be lessened by plans to provide lateral flow tests to households. It would also give companies scope to operate their own schemes, provided — as the government insists — these respect equality legislation.

Where scepticism is merited is in the ability of a government that has mishandled most of its Covid response bar vaccinations to manage a complex and sensitive scheme. A functioning app, along with sound and comprehensive guidelines, are needed fast. If the gap between intention and implementation is as wide as it has so often been over the past 15 months, chaos and confusion — or the two-tier society critics worry about — could still ensue.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

肺纤维化生物科技公司Avalyn Pharma申请首次公开募股(IPO)

一家生物技术公司正开发可吸入剂型的已获批肺纤维化口服药,计划赴公开市场融资以支持其后期研发。
11小时前

凯勒拉治疗学公司在生物技术领域创纪录的IPO中融资6.25亿美元

最新的生物科技公司首次公开募股创下历史新高。
1天前

法国将迎来最拥挤的大选角逐场:谁将取代马克龙?

左翼和中间阵营的分裂,助长了极右翼问鼎爱丽舍宫的希望。

全球失衡的凯恩斯式解决方案

自20世纪40年代以来,经济学家一直在提出各种方案,试图修复由国际储备货币所造成的结构性问题。

伊朗战争在多大程度上影响美国通货膨胀?

日元接下来何去何从?英国今年的经济增长是否正在回升?

华尔街顶级律师事务所如何沦为内幕交易的输送渠道

并购咨询已演变成庞大的法律业务,却让律所在机密信息被滥用方面更加脆弱。
设置字号×
最小
较小
默认
较大
最大
分享×